{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"}],"units":"Participants"}],"title":"Hemoglobin < 0.8 × lower limit of normal and > 20% decrease from baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"}],"units":"Participants"}],"title":"Hemoglobin > 1.3 × upper limit of normal (ULN) and > 30% increase from baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Lymphocytes < 0.5 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Lymphocytes > 20 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Neutrophils < 1.0 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Platelets < 75 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Platelets ≥ 700 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Leukocytes ≤ 2.8 × 10^9/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"title":"Leukocytes ≥ 16.0 × 10^9/L"}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"description":"The number of patients with each type of event is summarized.","groups":[{"description":"6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).","id":"OG000","title":"UGN-102"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received any dose of UGN-102 and who had a post-baseline laboratory value, except for hemoglobin, which required non-missing laboratory values at baseline and post-baseline.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With Post-baseline Potentially Clinically Significant (PCS) Hematology Values","type":"SECONDARY","unitOfMeasure":"Participants"}